Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia - DCOG Protocol ALL-11

Princess Máxima Center for pediatric oncology0 个研究点目标入组 819 人开始时间: 2012年7月13日最近更新: 2023年7月18日

研究概览

暂无简介。

•1.Newly diagnosed patients with T-lineage or precursor-B lineage ALL (patients with mature B-ALL are not eligible)
•2.Age between = 1 and < 19 years
•3.Informed consent signed by parents/guardians and patient if 12 years or older
•4.Diagnosis ALL confirmed by DCOG laboratory
•5.Patient should be treated in a Dutch Childhood Oncology Centre
•6.Patient should be >3 months settled in The Netherlands at diagnosis
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 818
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Age = 19 years at diagnosis
•2.Age < 366 days at diagnosis (infant ALL); these patients are eligible for the Interfant protocol
•3.Patients with secondary ALL
•4.Patients with mature B-ALL (immunophenotypical or documented presence of karyotype t(8;14), t(2;8), t(8;22) and breakpoint as in B-ALL)
•5.Patients with relapsed ALL
•6.Pre-existing contra-indications for treatment according to (parts of) protocol ALL-11.
•7.Essential data missing (in consultation with the protocol chairman)
•8.Treatment with systemic corticosteroids and/or cytostatics in a 4-week interval prior to diagnosis. One exception is the use of corticosteroids as emergency treatment.
•9.Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR/ABL fusion transcript). These patients will be transferred to the EsPhALL protocol in induction according to the guidelines of the EsPhALL protocol.

发起方

Princess Máxima Center for pediatric oncology